Close
Achema middle east
swop processing & packaging

Vidacare study reveals IO infusion equivalent to IV in Therapeutic Hypothermia

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Optimizing DMF Quality for Successful Health Authority Filings

A Drug Master File (DMF) is a confidential regulatory...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

The Way Forward for the Healthcare Data Ecosystem

The transformation of worldwide healthcare by way of digital...

Vidacare’s study to compare Intraosseous (IO) vascular access to infuse chilled saline as effectively as peripheral intravenous (IV) access to achieve therapeutic hypothermia showed no statistical difference between the two routes.

 

The study was named ‘Infusing Chilled Saline Through the Intraosseous Route is Equivalent to Infusion Through the Intravenous Route in Reducing the Core Temperature in Swine.’

It investigated whether Intraosseous (IO) vascular access may be effectively used to infuse chilled saline to achieve Therapeutic hypothermia (TH) as an alternative to peripheral intravenous (IV) access.

It was observed that IO and IV temperature reductions were statistically equivalent, and concluded no clinical or statistical difference between IV and IO when comparing the two routes for infusion of chilled saline for therapeutic hypothermia.

The research used the EZ-IO Intraosseous Infusion System, a battery-powered device to establish immediate vascular access and the only IO device which is FDA cleared for humeral insertion.

 

Latest stories

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Optimizing DMF Quality for Successful Health Authority Filings

A Drug Master File (DMF) is a confidential regulatory...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

The Way Forward for the Healthcare Data Ecosystem

The transformation of worldwide healthcare by way of digital...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »